Schizophrenia is a chronic mental health condition that most commonly develops in the third decade of life, but may emerge during adolescence, although in rare cases it can also present in childhood. Pre-adult onset is associated with substantial morbidity, functional impairment, and long-term disability. Accurately diagnosing schizophrenia in youth is particularly challenging, as its symptoms frequently overlap with or are misattributed to other psychiatric or developmental conditions. Conversely, misdiagnosis can also occur when psychotic symptoms are present in patients suffering from other conditions. Establishing an accurate and timely diagnosis is therefore critical to prevent errors in treatment and to optimize prognosis and functional outcomes. Antipsychotic medications are first-line interventions for schizophrenia in youth, with second-generation antipsychotics (SGAs) having the strongest evidence base in this population. Randomized controlled trials and open-label studies support the efficacy of risperidone, aripiprazole, olanzapine, quetiapine, paliperidone, lurasidone, and brexpiprazole in reducing psychotic symptoms in adolescents. In contrast, ziprasidone and asenapine have not demonstrated clear benefit in treatment of schizophrenia in youth. Similar to studies in adults, evidence from pediatric clinical trials suggests that clozapine remains the most effective option for treatment-resistant adolescent schizophrenia, although its use requires close monitoring for hematologic and other adverse effects. While SGAs are generally favored over first-generation antipsychotics (FGAs) in youth because of their reduced propensity for causing extrapyramidal side effects as well as a stronger evidence base to support their use, their safety profiles require careful consideration. Weight gain, metabolic syndrome, sedation, extrapyramidal symptoms, and endocrine effects have been reported in youth with schizophrenia. Such side effects can significantly impact adherence and long-term physical health, necessitating the need for ongoing monitoring and thoughtful agent selection tailored to each patient's individual clinical profile and risk factors. Overall, current evidence supports SGAs as the foundation of psychopharmacologic treatment for schizophrenia in pediatric-aged patients, with clozapine reserved for refractory cases. However, the relative paucity of pediatric-specific data compared with adult populations underscores the importance of continued research to guide clinical practice. In the meantime, accurate diagnosis, early intervention, and vigilant monitoring of both therapeutic response and side effects remain essential to optimizing outcomes for youth with schizophrenia.
Findling et al. (Wed,) studied this question.